MDTHealthcare · Medical DevicesThe 28 Wall Street analysts covering Medtronic PLC hold a median 12-month price target of $106 — +19.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 23 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Medtronic PLC on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Momentum (56): The shares have been drifting down relative to others.
Size (2): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MDT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +19.8% from it.
Of the 20 most recent actions, 10 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Sept 2026 | UBS | Maintains | Buy | $100 → $110 |
| 2 Sept 2026 | B of A Securities | Maintains | Buy | $95 → $110 |
| 2 Sept 2026 | Baird | Maintains | Neutral | $91 → $100 |
| 2 Sept 2026 | RBC Capital | Reiterates | Outperform | $118 |
| 2 Sept 2026 | Stifel | Maintains | Hold | $80 → $95 |
| 2 Sept 2026 | Truist Securities | Reiterates | Hold | $86 → $99 |
| 2 Sept 2026 | Wells Fargo | Maintains | Overweight | $102 → $104 |
| 1 Sept 2026 | BTIG | Maintains | Buy | $91 → $100 |
| 1 Sept 2026 | Needham | Reiterates | Buy | $114 |
| 28 Aug 2026 | TD Cowen | Maintains | Buy | $100 → $110 |
| 27 Aug 2026 | Needham | Maintains | Buy | $101 → $114 |
| 18 Aug 2026 | BTIG | Reiterates | Buy | $91 |
| 18 Aug 2026 | BTIG | Reiterates | Buy | — |
| 28 July 2026 | UBS | Upgrade | Buy | — |
| 28 July 2026 | UBS | Upgrade | Buy | $85 → $100 |
| 10 July 2026 | TD Cowen | Maintains | Buy | — |
| 10 July 2026 | TD Cowen | Maintains | Buy | $119 → $100 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $106 → $105 |
| 17 June 2026 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Sept 2026, Medtronic PLC returned −4.6% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 33% of US stocks
Cheaper than 40% of US stocks
Cheaper than 40% of US stocks
Cheaper than 27% of US stocks
Higher than 60% of US stocks
Higher than 71% of US stocks
Higher than 78% of US stocks
Higher than 78% of US stocks
Higher than 76% of US stocks
Higher than 65% of US stocks
Higher than 77% of US stocks
Higher than 66% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medtronic PLC has a market value of $116.1B and an enterprise value of $136.1B.
Revenue in the twelve months to 31 July 2026: $37.5B. The latest quarter grew 13.7% year on year.
Net income over the same four quarters: $5.3B, a 14.0% net margin.
Diluted earnings per share, trailing twelve months: $4.06.
Free cash flow in the twelve months to 31 July 2026: $6.1B.
Medtronic PLC spent $1.2B on share buybacks and $3.6B on dividends in the twelve months to 31 July 2026.
Trailing P/E: 22.6×; forward P/E: 14.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 3.17%, paying out 70% of earnings.
Medtronic PLC employs 95,000 people — $395K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Medtronic PLC — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Medtronic (MDT) closed at $89.3, down 1.62% from its prior close, a decline that outpaced the broader market. The article highlights the stock's weaker-than-market performance in the latest trading session.
Why it matters — MDT watchers would note the stock's underperformance relative to the broader market, potentially signaling weakness in investor sentiment.
Medtronic received a buy rating from Seeking Alpha with a $106.33 price target, citing a 3% dividend yield and strong free cash flow growth. The firm also noted that Q1 FY27 results exceeded expectations, with 7% normalized revenue growth, strength in Cardiovascular and Neuroscience segments, and raised revenue and EPS guidance, though margin expansion is expected to come gradually.
Why it matters — A Medtronic investor would care because the piece highlights above-expectation quarterly results, raised full-year guidance, and a strong dividend, all factors supporting the company's outlook.
Medtronic reported solid Q1 FY27 results with approximately 7% organic revenue growth and raised its full-year guidance to 7.25–7.75%. Newer businesses, particularly Cardiac Ablation Solutions, are becoming meaningful contributors, and the planned MiniMed separation is expected to make the company smaller but more profitable with sharper focus.
Why it matters — The raised guidance, growing contribution from newer businesses, and the MiniMed separation's expected margin benefits signal a more robust and focused growth profile for Medtronic shareholders.
Benzinga reports that Wall Street's most accurate analysts are weighing in on three health care stocks offering high dividend yields. The article notes that investors often turn to dividend-paying stocks during market turbulence, as these companies typically have strong free cash flows and reward shareholders.
Why it matters — Medtronic watchers would care because the piece discusses dividend-yielding health care stocks, a category that includes Medtronic, and signals analyst attention on such companies.
The article discusses Jim Cramer calling Medtronic a "quandary," noting that the medical device company's business grew bloated and its growth slowed over time. It adds that Medtronic has since overhauled its business and is beginning to see stronger results.
Why it matters — A MDT watcher would care because it highlights both the company's past growth struggles and the early signs of improvement following its business overhaul.
The 28 Wall Street analysts covering Medtronic PLC have a median 12-month price target of $106, with estimates ranging from $85 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 28 analysts covering Medtronic PLC, 19 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medtronic PLC 87 out of 100 across roughly 4,600 US stocks as at 23 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 23 Sept 2026, Medtronic PLC ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 28 analysts implies +19.8% from the last close, and Ticker Nerd's factor model ranks Medtronic PLC 87 out of 100 as at 23 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Medtronic PLC publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $121 over the next 12 months.
Medtronic PLC returned -4.6% over the 12 months to 24 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions.
The most recent item we track (Zacks Investment Research, 23 Sept 2026): "Here's Why Medtronic (MDT) Fell More Than Broader Market". Medtronic (MDT) closed at $89.3, down 1.62% from its prior close, a decline that outpaced the broader market. The article highlights the stock's weaker-than-market performance in the latest trading session.
Medtronic plc is a global medical technology company that develops, manufactures, and sells device-based therapies and healthcare solutions. Its portfolio spans cardiovascular care, neuroscience, medical surgical products, and diabetes management, supporting the diagnosis, treatment, and monitoring of a wide range of chronic and complex conditions. Medtronic supplies hospitals, clinics, physicians, and other healthcare providers with products such as cardiac rhythm devices, neuromodulation systems, surgical instruments, insulin pumps, and patient monitoring technologies. The company serves healthcare systems across the United States and international markets, making it an important participant in modern medical device supply chains and clinical care delivery. Headquartered in Dublin, Ireland, Medtronic plc focuses on technologies used in everyday care and advanced procedures, helping healthcare professionals address conditions across many specialties.
CEO Mr. Geoffrey Straub Martha · 95,000 employees · Ireland · https://www.medtronic.com
